41,697 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by Legal & General Group Plc

Legal & General Group Plc purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,697 shares of the company’s stock, valued at approximately $623,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ProShare Advisors LLC raised its stake in shares of Corvus Pharmaceuticals by 7.7% during the 4th quarter. ProShare Advisors LLC now owns 13,764 shares of the company’s stock valued at $106,000 after buying an additional 979 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Corvus Pharmaceuticals by 5.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company’s stock worth $263,000 after buying an additional 1,696 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Corvus Pharmaceuticals by 6.0% during the third quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company’s stock worth $238,000 after acquiring an additional 1,812 shares during the period. Global Retirement Partners LLC acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $30,000. Finally, Deutsche Bank AG raised its position in Corvus Pharmaceuticals by 4.5% during the fourth quarter. Deutsche Bank AG now owns 56,039 shares of the company’s stock valued at $432,000 after acquiring an additional 2,400 shares in the last quarter. 46.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRVS has been the topic of several recent research reports. LADENBURG THALM/SH SH upgraded Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Weiss Ratings raised shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.33.

Corvus Pharmaceuticals Trading Down 3.2%

NASDAQ:CRVS opened at $13.93 on Wednesday. The stock has a 50 day moving average of $14.43 and a two-hundred day moving average of $14.43. Corvus Pharmaceuticals, Inc. has a 12 month low of $5.64 and a 12 month high of $26.95. The firm has a market cap of $1.17 billion, a P/E ratio of -22.84 and a beta of 0.87.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, research analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.79 earnings per share for the current year.

Insider Buying and Selling

In other news, Director David Moore acquired 21,700 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $11.53 per share, for a total transaction of $250,201.00. Following the acquisition, the director owned 21,700 shares of the company’s stock, valued at approximately $250,201. This trade represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 19.70% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.